Skip to main content

Apoptosis Modelling for Treatment Decisions in Colorectal Cancer

Objective

"With the arrival of new colorectal cancer (CRC) therapeutics targeting specific cell signalling pathways, such as anti-EGFR therapy, personalised cancer treatment is at the door step of clinical practise. This progress in drug development contrasts strikingly with current clinical practice, where decision making depends largely on clinical factors such as tumour staging and age of patient, with the success of such treatments being largely unpredictable. 5-FU-based chemotherapy represents the main stay of CRC therapy. DNA damaging agents such as 5-FU and anti-EGFR therapy seek to induce tumour regression through induction of apoptosis or sensitization to apoptosis. Dysfunctional apoptosis is well recognized as a key contributing factor in chemotherapy resistance. The aim of the APODECIDE consortium is to develop systems medicine tools that predict treatment responses in CRC patients to 5-FU-based chemotherapy and anti-EGFR therapy, based on a systems analysis of apoptosis and EGFR signalling pathways. Based on previous clinical proof-of-concept studies that demonstrated the unique potential of such approaches in predicting tumour resistance, the APO-DECIDE consortium aims to deliver new clinical decision making tools that enable personalised medicine approaches and ‘smart’ clinical trials design in the future. The SMEs will benefit from the project through the development of systems-based combinatorial biomarkers adapted to formalin fixed paraffin-embedded material, the routine material used in clinical histopathology, hence providing a unique opportunity for marketing and exploitation. SMEs and their academic partners will also develop computational whole body models reflecting drug pharmacodynamics and pharmacokinetics in patient cohorts, providing a unique market niche in the field clinical oncology."

Call for proposal

FP7-HEALTH-2012-INNOVATION-1
See other projects for this call

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND
Address
Saint Stephen's Green 123
2 Dublin
Ireland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 932 803,80
Administrative Contact
Jochen Prehn (Prof.)

Participants (6)

ONCOMARK LIMITED
Ireland
EU contribution
€ 508 000
Address
172 Rathgar Road Rathgar
Dublin 6 Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Mairin Rafferty (Ms.)
THE QUEEN'S UNIVERSITY OF BELFAST
United Kingdom
EU contribution
€ 353 442
Address
University Road Lanyon Building
BT7 1NN Belfast
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Colleen Spence (Mrs.)
UNIVERSITE RENE DESCARTES - PARIS 5
France
EU contribution
€ 362 400
Address
Rue De L'ecole De Medecine 12
75270 Paris
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Adeline Lassaux (Dr.)
OPTIMATA LTD
Israel
EU contribution
€ 461 160
Address
20 Zichron Yaa'kov St.
6299920 Tel Aviv
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Marina Kleiman (Dr.)
PINTAIL LTD
Ireland
EU contribution
€ 64 800
Address
Springhill Avenue 77
A94 K542 Blackrock
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ciaran Clissmann (Mr.)
KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET
Germany
EU contribution
€ 316 876,20
Address
Theodor Stern Kai 7
60596 Frankfurt Am Main
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Simone Fulda (Prof.)